

Craig Coleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9512072/publications.pdf>

Version: 2024-02-01

352
papers

12,548
citations

24978

57
h-index

39575

94
g-index

373
all docs

373
docs citations

373
times ranked

15619
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins and Cancer Risk. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 74.	3.8	529
2	Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1410.	3.8	448
3	Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 244-252.	2.2	331
4	Understanding heterogeneity in meta-analysis: the role of meta-regression. <i>International Journal of Clinical Practice</i> , 2009, 63, 1426-1434.	0.8	323
5	Dosing Frequency and Medication Adherence in Chronic Disease. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 527-539.	2.2	306
6	Association of Inhaled Corticosteroids and Long-Acting β_2 -Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1485.	3.8	231
7	The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2261-2266.	4.3	198
8	Diagnostic Accuracy of Cardiac Positron Emission Tomography Versus Single Photon Emission Computed Tomography for Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 700-707.	1.3	198
9	Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis. <i>Annals of Family Medicine</i> , 2013, 11, 452-459.	0.9	190
10	Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2014, 30, 1317-1325.	0.9	172
11	Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: A meta-analysis. <i>Journal of Critical Care</i> , 2008, 23, 91-100.	1.0	166
12	Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 73-81.	2.2	164
13	Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2010, 87, 98-107.	1.1	164
14	Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 473-480.	4.6	156
15	Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1167-1175.	2.2	155
16	The Impact of Coenzyme Q10 on Systolic Function in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, 464-472.	0.7	142
17	Green Tea Catechins Decrease Total and Low-Density Lipoprotein Cholesterol: A Systematic Review and Meta-Analysis. <i>Journal of the American Dietetic Association</i> , 2011, 111, 1720-1729.	1.3	134
18	The Effect of Grape Seed Extract on Cardiovascular Risk Markers: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Dietetic Association</i> , 2011, 111, 1173-1181.	1.3	131

#	ARTICLE	IF	CITATIONS
19	Effects of Garlic on Blood Pressure in Patients with and Without Systolic Hypertension: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1766-1771.	0.9	125
20	Effect of Cinnamon on Glucose Control and Lipid Parameters. <i>Diabetes Care</i> , 2008, 31, 41-43.	4.3	121
21	Costâ€“Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 110, 845-851.	0.7	120
22	Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. <i>Diabetic Medicine</i> , 2007, 24, 486-493.	1.2	114
23	Effect of dosing frequency on chronic cardiovascular disease medication adherence. <i>Current Medical Research and Opinion</i> , 2012, 28, 669-680.	0.9	113
24	Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0125879.	1.1	112
25	The effects of Panax ginseng on quality of life. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 5-15.	0.7	109
26	Electrocardiographic and Hemodynamic Effects of a Multicomponent Dietary Supplement Containing Ephedra and Caffeine. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 216.	3.8	94
27	Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 405-411.	0.4	93
28	Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. <i>American Journal of Medicine</i> , 2019, 132, 1078-1083.	0.6	93
29	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	92
30	The Effects of Barley-Derived Soluble Fiber on Serum Lipids. <i>Annals of Family Medicine</i> , 2009, 7, 157-163.	0.9	91
31	The impact of garlic on lipid parameters: a systematic review and meta-analysis. <i>Nutrition Research Reviews</i> , 2009, 22, 39-48.	2.1	88
32	The Comparative Efficacy of Plant Sterols and Stanols on Serum Lipids: A Systematic Review and Meta-Analysis. <i>Journal of the American Dietetic Association</i> , 2010, 110, 719-726.	1.3	87
33	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2017, 48, 2142-2149.	1.0	87
34	Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 35, 521-527.	0.6	86
35	Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. <i>Thrombosis Journal</i> , 2014, 12, 14.	0.9	86
36	Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. <i>Current Medical Research and Opinion</i> , 2016, 32, 2047-2053.	0.9	86

#	ARTICLE	IF	CITATIONS
37	Effect of statins on atrial fibrillation after cardiac surgery: A duration- and dose-response meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 364-372.	0.4	84
38	Prognostic Accuracy of Clinical Prediction Rules for Early Post-Pulmonary Embolism All-Cause Mortality. <i>Chest</i> , 2015, 147, 1043-1062.	0.4	81
39	Chapter 8: Meta-analysis of Test Performance When There is a "Gold Standard". <i>Journal of General Internal Medicine</i> , 2012, 27, 56-66.	1.3	79
40	Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. <i>BMC Family Practice</i> , 2012, 13, 5.	2.9	79
41	Neurothrombectomy Devices for the Treatment of Acute Ischemic Stroke: State of the Evidence. <i>Annals of Internal Medicine</i> , 2011, 154, 243.	2.0	77
42	Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2014, 30, 2461-2469.	0.9	77
43	Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1473.	3.8	77
44	Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , 2008, 26, 622-629.	0.3	76
45	The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2008, 24, 1359-1362.	0.9	74
46	Effect of pharmacist intervention on glycemic control in diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, 145-152.	1.1	73
47	Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2012, 28, 49-56.	0.9	73
48	Preoperative statins and infectious complications following cardiac surgery. <i>Current Medical Research and Opinion</i> , 2007, 23, 1783-1790.	0.9	72
49	Almonds Have a Neutral Effect on Serum Lipid Profiles: A Meta-Analysis of Randomized Trials. <i>Journal of the American Dietetic Association</i> , 2009, 109, 865-873.	1.3	72
50	The Effect of Adding Plant Sterols or Stanols to Statin Therapy in Hypercholesterolemic Patients: Systematic Review and Meta-Analysis. <i>Journal of the American College of Nutrition</i> , 2009, 28, 517-524.	1.1	70
51	Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 31, 817-820.	0.6	64
52	Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors. <i>Journal of the American Heart Association</i> , 2020, 9, e014402.	1.6	64
53	Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , 2014, 17, 52-64.	1.0	62
54	Statin use and the prevention of venous thromboembolism: a meta-analysis. <i>International Journal of Clinical Practice</i> , 2010, 64, 1375-1383.	0.8	61

#	ARTICLE	IF	CITATIONS
55	AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes. <i>British Journal of Sports Medicine</i> , 2016, 50, 84-92.	3.1	61
56	Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation. <i>PLoS ONE</i> , 2012, 7, e47473.	1.1	60
57	Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2012, 66, 53-63.	0.8	60
58	Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 287-294.	1.1	59
59	Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. <i>Heart Rhythm</i> , 2007, 4, 461-468.	0.3	56
60	Safety of amiodarone in the prevention of postoperative atrial fibrillation: A meta-analysis. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 829-837.	0.5	55
61	Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase. <i>American Journal of Medicine</i> , 2007, 120, 706-712.	0.6	55
62	The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 21-28.	1.0	54
63	Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1571-1581.	1.3	54
64	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models. <i>PLoS ONE</i> , 2013, 8, e62183.	1.1	53
65	Impact of Epicardial Anterior Fat Pad Retention on Postcardiothoracic Surgery Atrial Fibrillation Incidence. <i>Journal of the American College of Cardiology</i> , 2007, 49, 298-303.	1.2	51
66	Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis. <i>International Journal of Cardiology</i> , 2016, 216, 104-109.	0.8	51
67	Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. <i>International Journal of Cardiology</i> , 2016, 215, 11-13.	0.8	50
68	Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1142-1153.	0.4	50
69	Pharmacologic Treatments for Chronic Obstructive Pulmonary Disease: A Mixed-€Treatment Comparison Meta-€analysis. <i>Pharmacotherapy</i> , 2009, 29, 891-905.	1.2	47
70	Impact of Intravenous Magnesium on Post-Cardiothoracic Surgery Atrial Fibrillation and Length of Hospital Stay: A Meta-Analysis. <i>Annals of Thoracic Surgery</i> , 2005, 80, 2402-2406.	0.7	46
71	The Effect of Metformin on Anthropometrics and Insulin Resistance in Patients Receiving Atypical Antipsychotic Agents. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1286-1292.	1.1	46
72	Impact of gender on statin efficacy. <i>Current Medical Research and Opinion</i> , 2007, 23, 565-574.	0.9	45

#	ARTICLE	IF	CITATIONS
73	Timing of recurrent venous thromboembolism early after the index event: A meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2013, 132, 420-426.	0.8	45
74	Impact of Prophylactic Postoperative β -Blockade on Post-Cardiothoracic Surgery Length of Stay and Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2012-2016.	0.9	44
75	Intravenous Magnesium Sulfate Enhances the Ability of Intravenous Ibutilide to Successfully Convert Atrial Fibrillation or Flutter. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 1331-1335.	0.5	43
76	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. <i>Thrombosis Journal</i> , 2016, 14, 14.	0.9	43
77	The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , 2010, 7, 755-760.	0.3	42
78	Assessing equivalence and noninferiority. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1144-1149.	2.4	42
79	Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 301-307.	1.8	42
80	Meta-Analysis to Assess the Quality of International Normalized Ratio Control and Associated Outcomes in Venous Thromboembolism Patients. <i>Thrombosis Research</i> , 2014, 134, 310-319.	0.8	41
81	Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. <i>Current Medical Research and Opinion</i> , 2016, 32, 1281-1290.	0.9	41
82	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. <i>Annals of Internal Medicine</i> , 2009, 151, 861-71.	2.0	41
83	The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2009, 84, e33-e37.	1.1	40
84	Gender differences in the diagnostic accuracy of SPECT myocardial perfusion imaging: A bivariate meta-analysis. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 53-63.	1.4	40
85	Inferior vena cava filters and postoperative outcomes in patients undergoing bariatric surgery: a meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 725-733.	1.0	40
86	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <i>Diabetic Medicine</i> , 2015, 32, 1530-1540.	1.2	40
87	AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis. <i>Clinical Journal of Sport Medicine</i> , 2016, 26, 1-11.	0.9	40
88	Emergency Department Discharge of Pulmonary Embolus Patients. <i>Academic Emergency Medicine</i> , 2018, 25, 995-1003.	0.8	40
89	Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54756.	1.1	39
90	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016, 116, S13-S23.	1.8	39

#	ARTICLE	IF	CITATIONS
91	Updating comparative effectiveness reviews: Current efforts in AHRQ's Effective Health Care Program. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1208-1215.	2.4	38
92	Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis. <i>Thrombosis Research</i> , 2015, 135, 888-896.	0.8	38
93	Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. <i>Heart Rhythm</i> , 2020, 17, e206-e219.	0.3	38
94	The relationship between statin use and atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2007, 23, 1177-1185.	0.9	37
95	Prolonged Versus Standard-Duration Venous Thromboprophylaxis in Major Orthopedic Surgery. <i>Annals of Internal Medicine</i> , 2012, 156, 720.	2.0	37
96	Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986853.	0.7	37
97	Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting. <i>Prehospital Emergency Care</i> , 2020, 24, 163-174.	1.0	37
98	Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. <i>International Journal of Clinical Practice</i> , 2010, 64, 1239-1244.	0.8	36
99	Increased Clinical Failures When Treating Acute Otitis Media with Macrolides: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2010, 44, 471-478.	0.9	36
100	REal-Life Evidence of stroke prevention in patients with atrial Fibrillation – The RELIEF study. <i>International Journal of Cardiology</i> , 2016, 203, 882-884.	0.8	36
101	Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample. <i>Atherosclerosis</i> , 2019, 286, 142-146.	0.4	36
102	Possible Gatifloxacin-Induced Fulminant Hepatic Failure. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1162-1167.	0.9	35
103	Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2007, 41, 433-437.	0.9	35
104	Number and Impact of Published Scholarly Works by Pharmacy Practice Faculty Members at Accredited US Colleges and Schools of Pharmacy (2001–2003). <i>American Journal of Pharmaceutical Education</i> , 2007, 71, 44.	0.7	35
105	Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis. <i>Clinical Therapeutics</i> , 2008, 30, 1416-1425.	1.1	35
106	A Meta-Analysis Evaluating the Impact of Chitosan on Serum Lipids in Hypercholesterolemic Patients. <i>Annals of Nutrition and Metabolism</i> , 2009, 55, 368-374.	1.0	35
107	Recombinant Human Growth Hormone in the Treatment of Patients With Cystic Fibrosis. <i>Pediatrics</i> , 2010, 126, e1211-e1226.	1.0	35
108	Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1841-1847.	1.8	35

#	ARTICLE	IF	CITATIONS
109	Indicators of atrial fibrillation risk in cardiac surgery patients on prophylactic amiodarone. <i>Annals of Thoracic Surgery</i> , 2004, 77, 1288-1292.	0.7	34
110	Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. <i>Journal of Medical Economics</i> , 2012, 15, 1088-1096.	1.0	34
111	Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. <i>International Journal of Clinical Practice</i> , 2009, 63, 613-623.	0.8	33
112	Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 916-925.	0.5	33
113	Comparative Effectiveness of Low-Molecular-Weight Heparins versus Other Anticoagulants in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Pharmacotherapy</i> , 2012, 32, 799-808.	1.2	33
114	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS/ACTS Substudy. <i>Clinical Cardiology</i> , 2016, 39, 565-569.	0.7	33
115	Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 472-479.	0.9	32
116	Walking Speed and Health-Related Quality of Life in Multiple Sclerosis. <i>Patient</i> , 2014, 7, 55-61.	1.1	32
117	Effect of Prophylactic Amiodarone on Clinical and Economic Outcomes After Cardiothoracic Surgery: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1409-1415.	0.9	31
118	Efficacy and Safety of Innovator versus Generic Drugs in Patients with Epilepsy: A Systematic Review. <i>Pharmacotherapy</i> , 2012, 32, 314-322.	1.2	31
119	Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. <i>International Journal of Cardiology</i> , 2016, 212, 171-173.	0.8	31
120	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1574541.	0.8	31
121	Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. <i>PLoS ONE</i> , 2016, 11, e0157769.	1.1	31
122	Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review. <i>BMJ Open</i> , 2013, 3, e003111.	0.8	30
123	Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 90-94.	0.7	30
124	Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 182S-187S.	0.7	30
125	The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. <i>Journal of Internal Medicine</i> , 2006, 260, 467-473.	2.7	29
126	Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 500-505.	1.1	29

#	ARTICLE	IF	CITATIONS
127	The Association Among Blood Transfusions, White Blood Cell Count, and the Frequency of Postâ€ Cardiothoracic Surgery Atrial Fibrillation: A Nested Cohort Study From the Atrial Fibrillation Suppression Trials I, II, and III. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2009, 23, 22-27.	0.6	29
128	Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. <i>Dermatology and Therapy</i> , 2012, 2, 9.	1.4	29
129	Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015, 31, 1831-1840.	0.9	29
130	Metaâ€ Analysis of Time in Therapeutic Range in Continuousâ€ Flow Left Ventricular Assist Device Patients Receiving Warfarin. <i>Artificial Organs</i> , 2018, 42, 700-704.	1.0	29
131	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with nonâ€ valvular atrial fibrillation and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2107-2114.	2.2	29
132	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , 2020, 36, 1081-1088.	0.9	29
133	Oral antiâ€ diabetic drugs for the prevention of Typeâ€ 2 diabetes. <i>Diabetic Medicine</i> , 2011, 28, 948-964.	1.2	28
134	Oral Antidiabetic Drugs and Regression from Prediabetes to Normoglycemia: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2012, 46, 469-476.	0.9	28
135	Rivaroxaban versus apixaban in nonâ€ valvular atrial fibrillation patients with endâ€ stage renal disease or receiving dialysis. <i>European Journal of Haematology</i> , 2020, 104, 328-335.	1.1	28
136	Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1632-1639.	0.5	27
137	Effectiveness and safety of rivaroxaban vs warfarin in people with nonâ€ valvular atrial fibrillation and diabetes: an administrative claims database analysis. <i>Diabetic Medicine</i> , 2018, 35, 1105-1110.	1.2	27
138	Evaluation of the Charlson Comorbidity Index to Predict Early Mortality in Implantable Cardioverter Defibrillator Patients. <i>Annals of Noninvasive Electrocardiology</i> , 2013, 18, 379-388.	0.5	26
139	Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. <i>Current Medical Research and Opinion</i> , 2016, 32, 1277-1279.	0.9	26
140	Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. <i>Current Medical Research and Opinion</i> , 2007, 23, 2849-2855.	0.9	25
141	Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS). <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 1547-1552.	0.4	25
142	Effect of Nonergot Dopamine Agonists on Symptoms of Restless Legs Syndrome. <i>Annals of Family Medicine</i> , 2008, 6, 253-262.	0.9	25
143	Outcomes of Perioperative Î²-Blockade in Patients Undergoing Noncardiac Surgery: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1181-1188.	0.9	25
144	Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 210-215.	1.2	25

#	ARTICLE	IF	CITATIONS
145	Contribution of intangible costs to the economic burden of multiple sclerosis. <i>Journal of Medical Economics</i> , 2010, 13, 626-632.	1.0	24
146	Estimating a minimal clinically important difference for the EuroQol 5-dimension health status index in persons with multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 66.	1.0	24
147	Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. <i>Current Medical Research and Opinion</i> , 2018, 34, 2125-2130.	0.9	24
148	Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. <i>Future Cardiology</i> , 2021, 17, 127-135.	0.5	24
149	Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. <i>Europace</i> , 2008, 10, 854-859.	0.7	23
150	Efficacy of statins in combination with interferon therapy in multiple sclerosis: A meta-analysis. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1494-1499.	0.5	23
151	Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 112, 355-362.	0.7	23
152	The Gender Paradox among Patients with Implantable Cardioverter-Defibrillators: A Propensity-Matched Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 878-884.	0.5	23
153	Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 2056-2066.	0.5	23
154	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	2.5	23
155	Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. <i>Heart Rhythm</i> , 2008, 5, 507-510.	0.3	22
156	Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. <i>International Journal of Clinical Practice</i> , 2012, 66, 171-182.	0.8	22
157	Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. <i>Europace</i> , 2009, 11, 892-895.	0.7	21
158	Patient Satisfaction with Warfarin- and Non-Warfarin-Containing Thromboprophylaxis Regimens for Atrial Fibrillation. <i>Journal of Investigative Medicine</i> , 2013, 61, 878-881.	0.7	21
159	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 933-938.e1.	0.6	21
160	Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 159-166.	1.4	21
161	US prevalence of upper gastrointestinal symptoms: a systematic literature review. <i>American Journal of Managed Care</i> , 2011, 17, e449-58.	0.8	21
162	Predictors of poor student performance at a single, Accreditation Council for Pharmacy Education-accredited school of pharmacy. <i>Currents in Pharmacy Teaching and Learning</i> , 2011, 3, 101-105.	0.4	20

#	ARTICLE	IF	CITATIONS
163	Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. <i>Clinical Cardiology</i> , 2020, 43, 524-531.	0.7	20
164	Atazanavir: a new protease inhibitor to treat HIV infection. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1365-1374.	0.5	19
165	Probable Topical Permethrin-Induced Neck Dystonia. <i>Pharmacotherapy</i> , 2005, 25, 448-450.	1.2	19
166	Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants. <i>Current Medical Research and Opinion</i> , 2014, 30, 1513-1520.	0.9	19
167	Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1043-1052.	1.9	19
168	External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 769-774.	0.7	19
169	Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 64-69.	1.4	19
170	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 349-358.	1.0	19
171	A hospital perspective on the cost-effectiveness of β -Blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery. <i>Clinical Therapeutics</i> , 2005, 27, 1963-1969.	1.1	18
172	An Evaluation of the Impact of Oral Magnesium Lactate on the Corrected QT Interval of Patients Receiving Sotalol or Dofetilide to Prevent Atrial or Ventricular Tachyarrhythmia Recurrence. <i>Annals of Noninvasive Electrocardiology</i> , 2006, 11, 163-169.	0.5	18
173	Feverfew for Migraine Prophylaxis: A Systematic Review. <i>Journal of Dietary Supplements</i> , 2009, 6, 91-103.	1.4	18
174	The Effect of Statin Therapy on Ventricular Tachyarrhythmias: A Meta-Analysis. <i>American Journal of Therapeutics</i> , 2012, 19, 16-23.	0.5	18
175	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 575-582.	0.7	18
176	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 27-36.	0.7	18
177	Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Pharmacotherapy</i> , 2019, 39, 196-203.	1.2	18
178	The use of protamine after radiofrequency catheter ablation: A pilot study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2007, 18, 155-158.	0.6	17
179	Factors associated with caregiver burden for atrial fibrillation patients. <i>International Journal of Clinical Practice</i> , 2012, 66, 984-990.	0.8	17
180	Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 105.	1.0	17

#	ARTICLE	IF	CITATIONS
181	Comparative Effectiveness of Combined Pharmacologic and Mechanical Thromboprophylaxis versus Either Method Alone in Major Orthopedic Surgery: A Systematic Review and Meta-analysis. <i>Pharmacotherapy</i> , 2013, 33, 275-283.	1.2	17
182	Cost-Effectiveness Analysis of Extended Duration Anticoagulation with Rivaroxaban to Prevent Recurrent Venous Thromboembolism. <i>Thrombosis Research</i> , 2014, 133, 743-749.	0.8	17
183	Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2015, 69, 1221-1235.	0.8	17
184	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 787-794.e4.	0.6	17
185	Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985089.	0.7	17
186	Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018, 9, 3151-3162.	0.2	17
187	Alendronate-Induced Auditory Hallucinations and Visual Disturbances. <i>Pharmacotherapy</i> , 2004, 24, 799-802.	1.2	16
188	Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 535-541.	0.5	16
189	Cost-Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable. <i>American Journal of Cardiology</i> , 2012, 109, 1020-1025.	0.7	16
190	The Healthcare Utilization and Cost of Treating Patients Experiencing Inappropriate Implantable Cardioverter Defibrillator Shocks: A Propensity Score Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1315-1323.	0.5	16
191	Mobility, walking and physical activity in persons with multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2014, 30, 1857-1862.	0.9	16
192	Cost-Effectiveness of Ranolazine Added to Standard-of-Care Treatment in Patients With Chronic Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2014, 113, 1306-1311.	0.7	16
193	Association between weekend admission and mortality for upper gastrointestinal hemorrhage: an observational study and meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 163-169.	1.0	16
194	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , 2017, 12, e0185022.	1.1	16
195	Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2010, 64, 1116-1120.	0.8	15
196	Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review. <i>Mayo Clinic Proceedings</i> , 2011, 86, 509-521.	1.4	15
197	Validation of the multivariable In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule within an all-payer inpatient administrative claims database. <i>BMJ Open</i> , 2015, 5, e009251.	0.8	15
198	Corrected QT in Ventricular Paced Rhythms: What Is the Validation for Commonly Practiced Assumptions?. <i>Cardiology</i> , 2015, 130, 207-210.	0.6	15

#	ARTICLE	IF	CITATIONS
199	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 149-157.	1.0	15
200	Association between weekend admission and in-hospital mortality for pulmonary embolism: An observational study and meta-analysis. <i>International Journal of Cardiology</i> , 2015, 194, 72-74.	0.8	14
201	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <i>Pharmacotherapy</i> , 2016, 36, 488-495.	1.2	14
202	Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2016, 32, 1117-1120.	0.9	14
203	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. <i>Internal and Emergency Medicine</i> , 2017, 12, 311-318.	1.0	14
204	Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2018, 5, 1141-1149.	1.4	14
205	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. <i>Thrombosis Research</i> , 2018, 168, 31-36.	0.8	14
206	Impact of Prophylactic Amiodarone on Length of Hospital Stay, Stroke, and Atrial Fibrillation After Cardiothoracic Surgery. <i>Pharmacotherapy</i> , 2005, 25, 320-324.	1.2	13
207	Benefits and risks associated with β -blocker prophylaxis in noncardiac surgery. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 523-530.	0.5	13
208	Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients. <i>BMJ Open</i> , 2013, 3, e002798.	0.8	13
209	College and School of Pharmacy Characteristics Associated With US News and World Report Rankings. <i>American Journal of Pharmaceutical Education</i> , 2013, 77, 55.	0.7	13
210	Derivation and validation of the In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule. <i>Current Medical Research and Opinion</i> , 2015, 31, 1461-1468.	0.9	13
211	Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. <i>Pharmacotherapy</i> , 2016, 36, 1109-1115.	1.2	13
212	Association between weekend admission for atrial fibrillation or flutter and in-hospital mortality, procedure utilization, length-of-stay and treatment costs. <i>International Journal of Cardiology</i> , 2016, 202, 427-429.	0.8	13
213	Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , 2017, 20, 200-203.	1.0	13
214	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 830-837.	0.7	13
215	The impact of non-medical switching among ambulatory patients: an updated systematic literature review. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1678563.	0.8	13
216	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. <i>Blood Advances</i> , 2020, 4, 4045-4051.	2.5	13

#	ARTICLE	IF	CITATIONS
217	Cost-benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 378-382.	0.5	12
218	Cost-Effectiveness of Amiodarone for Prophylaxis of Atrial Fibrillation After Cardiothoracic Surgery. <i>Pharmacotherapy</i> , 2006, 26, 499-504.	1.2	12
219	Association between perioperative NSAID use and post-cardiothoracic surgery atrial fibrillation, blood transfusions, and cardiovascular outcomes: a nested cohort study from the AF Suppression Trials (AFIST) I, II and III. <i>Current Medical Research and Opinion</i> , 2008, 24, 1131-1136.	0.9	12
220	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, S45-S60.	1.8	12
221	Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. <i>Cardiovascular Diabetology</i> , 2021, 20, 52.	2.7	12
222	Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals. <i>Clinical Therapeutics</i> , 2006, 28, 1054-1062.	1.1	11
223	Effect of Magnesium L-Lactate on Blood Pressure in Patients with an Implantable Cardioverter Defibrillator. <i>Annals of Pharmacotherapy</i> , 2009, 43, 559-576.	0.9	11
224	External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches. <i>Thrombosis Journal</i> , 2016, 14, 7.	0.9	11
225	Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 328-329.	1.8	11
226	Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 279-292.	1.9	11
227	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 491-497.	2.3	11
228	Physicians' perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey. <i>PLoS ONE</i> , 2020, 15, e0225867.	1.1	11
229	Economic Analysis of Intravenous Plus Oral Amiodarone, Atrial Septal Pacing, and Both Strategies to Prevent Atrial Fibrillation After Open Heart Surgery. <i>Pharmacotherapy</i> , 2004, 24, 1013-1019.	1.2	10
230	Use of Preoperative CHA ₂ DS ₂ -VASc Score to Predict the Risk of Atrial Fibrillation After Cardiothoracic Surgery: A Nested Case-Control Study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III. <i>Pharmacotherapy</i> , 2013, 33, 489-495.	1.2	10
231	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 1093-1102.	2.4	10
232	Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. <i>Pharmacotherapy</i> , 2018, 38, 610-618.	1.2	10
233	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 339-345.	1.0	10
234	Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. <i>PLoS ONE</i> , 2020, 15, e0225301.	1.1	10

#	ARTICLE	IF	CITATIONS
235	Effect of Practitioner Education on Adherence to Asthma Treatment Guidelines. <i>Annals of Pharmacotherapy</i> , 2003, 37, 956-961.	0.9	9
236	Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). <i>Internal and Emergency Medicine</i> , 2017, 12, 419-422.	1.0	9
237	Effectiveness and safety of rivaroxaban vs. warfarin in patients with nonvalvular atrial fibrillation and heart failure. <i>ESC Heart Failure</i> , 2019, 6, 10-15.	1.4	9
238	Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. <i>Diabetic Medicine</i> , 2020, 37, 44-52.	1.2	9
239	Journal publications by pharmacy practice faculty evaluated by institution and region of the United States (2001-2003). <i>Pharmacy Practice</i> , 2007, 5, 151-6.	0.8	9
240	The Effect of Phytosterols on Quality of Life in the Treatment of Benign Prostatic Hyperplasia. <i>Pharmacotherapy</i> , 2002, 22, 1426-1432.	1.2	8
241	Delivery of esomeprazole magnesium through nasogastric and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1882-1887.	0.5	8
242	Reducing adverse self-medication behaviors in older adults with the Next Generation Personal Education Program (PEP-NG): Design and methodology. <i>Patient Preference and Adherence</i> , 2009, 3, 323.	0.8	8
243	Neurology: Effect of Non-Ergot Dopamine Agonists on Health-Related Quality of Life of Patients with Restless Legs Syndrome. <i>Annals of Pharmacotherapy</i> , 2009, 43, 813-821.	0.9	8
244	A Clinician's Perspective on Rating the Strength of Evidence in a Systematic Review. <i>Pharmacotherapy</i> , 2009, 29, 1017-1029.	1.2	8
245	The Impact of Antiplatelet and Anticoagulant Therapies on Gastrointestinal Symptoms in Patients with Atrial Fibrillation: A Systematic Review. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1220-1231.	0.9	8
246	Impact of angina frequency on health utility values of patients with chronic stable angina. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 39.	1.0	8
247	Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective. <i>BMJ Open</i> , 2015, 5, e008861.	0.8	8
248	Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. <i>Current Medical Research and Opinion</i> , 2017, 33, 1033-1043.	0.9	8
249	Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. <i>Heart Lung and Circulation</i> , 2018, 27, 390-393.	0.2	8
250	Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 366-372.	1.0	8
251	Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. <i>Journal of Medical Economics</i> , 2019, 22, 751-759.	1.0	8
252	Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices. <i>PLoS ONE</i> , 2018, 13, e0191657.	1.1	8

#	ARTICLE	IF	CITATIONS
253	Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study. <i>Current Medical Research and Opinion</i> , 2022, 38, 937-945.	0.9	8
254	Cost Effectiveness of Ibutilide With Prophylactic Magnesium in the Treatment of Atrial Fibrillation. <i>Pharmacoeconomics</i> , 2004, 22, 877-883.	1.7	7
255	The prognostic impact of pre-implantation hyponatremia on morbidity and mortality among patients with left ventricular dysfunction and implantable cardioverter-defibrillators. <i>Europace</i> , 2014, 16, 47-54.	0.7	7
256	Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients. <i>Thrombosis and Haemostasis</i> , 2014, 111, 103-110.	1.8	7
257	Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 1697-1703.	0.9	7
258	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	0.8	7
259	Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2019, 35, 1867-1872.	0.9	7
260	Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review. <i>BMJ Open</i> , 2020, 10, e040499.	0.8	7
261	Short-Term Consequences of Angiographically-Confirmed Coronary Stent Thrombosis. <i>PLoS ONE</i> , 2013, 8, e77330.	1.1	7
262	Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1370-1374.	0.5	6
263	Association between weekend admission for intracerebral and subarachnoid hemorrhage and in-hospital mortality. <i>International Journal of Cardiology</i> , 2016, 212, 26-28.	0.8	6
264	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 513-519.	1.0	6
265	External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and Active Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1476-1482.	2.3	6
266	Treatment patterns, glycemic control and bodyweight with canagliflozin 300mg versus GLP1RAs in Type II diabetes patients. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 889-905.	0.6	6
267	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. <i>European Journal of Haematology</i> , 2019, 102, 143-149.	1.1	6
268	Specialist physician perspectives on non-medical switching of prescription medications. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1738637.	0.8	6
269	Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. <i>Journal of Clinical Epidemiology</i> , 2021, 135, 170-175.	2.4	6
270	Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 685-688.	0.5	5

#	ARTICLE	IF	CITATIONS
271	Systematic review: comparative effectiveness of adjunctive devices in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention of native vessels. BMC Cardiovascular Disorders, 2011, 11, 74.	0.7	5
272	External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Services Research, 2016, 16, 610.	0.9	5
273	External validation of the In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) multivariable prediction rule. International Journal of Clinical Practice, 2016, 70, 82-88.	0.8	5
274	Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. Thrombosis Research, 2016, 141, 8-10.	0.8	5
275	External validation of three risk stratification rules in patients presenting with pulmonary embolism and cancer. Supportive Care in Cancer, 2019, 27, 921-925.	1.0	5
276	Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. BMJ Open Diabetes Research and Care, 2019, 7, e000704.	1.2	5
277	Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. Thrombosis Journal, 2020, 18, 6.	0.9	5
278	The effect of Echinacea on upper respiratory infection symptom severity and quality of life. Connecticut Medicine, 2006, 70, 93-7.	0.2	5
279	Comparative Safety and Efficacy of Urokinase and Recombinant Tissue Plasminogen Activator for Peripheral Arterial Occlusion: A Meta-Analysis. Pharmacotherapy, 2006, 26, 51-60.	1.2	4
280	Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review. International Journal of Clinical Practice, 2011, 65, 749-763.	0.8	4
281	The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2018, 34, 1081-1087.	0.9	4
282	The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. Current Medical Research and Opinion, 2018, 34, 1501-1511.	0.9	4
283	Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. International Journal of Cardiology, 2018, 273, 34-38.	0.8	4
284	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. American Journal of Medicine, 2019, 132, 498-504.	0.6	4
285	REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE. Journal of the American College of Cardiology, 2020, 75, 2209.	1.2	4
286	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research, 2019, 6, 84-94.	0.6	4
287	Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. Connecticut Medicine, 2007, 71, 93-5.	0.2	4
288	Assessing the Usefulness of Health-Related Quality-of-Life Trials: A Clinician's Perspective Using Two COPD Examples. Annals of Pharmacotherapy, 2009, 43, 1496-1505.	0.9	3

#	ARTICLE	IF	CITATIONS
289	Quality measures for anticoagulation care. <i>Current Medical Research and Opinion</i> , 2016, 32, 1685-1692.	0.9	3
290	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. <i>Internal and Emergency Medicine</i> , 2017, 12, 613-619.	1.0	3
291	Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. <i>Clinical Cardiology</i> , 2018, 41, 119-125.	0.7	3
292	AHRQ Series on Improving Translation of Evidence: Linking Evidence Reports and Performance Measures to Help Learning Health Systems Use New Information for Improvement. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 706-710.	0.4	3
293	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	3
294	Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1829883.	0.8	3
295	Burden-of-Illness Associated with Bleeding-Related Hospitalizations in Atrial Fibrillation Patients: Findings from the Nationwide Readmission Database. <i>TH Open</i> , 2020, 04, e211-e217.	0.7	3
296	Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 1493-1500.	0.9	3
297	Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills. <i>Current Medical Research and Opinion</i> , 2022, 38, 19-26.	0.9	3
298	Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial. <i>Open Cardiovascular Medicine Journal</i> , 2015, 9, 83-88.	0.6	3
299	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study. <i>Blood</i> , 2018, 132, 1241-1241.	0.6	3
300	Prescriber and pharmacist responses to intervention letters for Connecticut Medicaid beneficiaries with asthma. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1142-1144.	0.5	2
301	Letter by Baker et al Regarding Article, "Benefits and Risks of Corticosteroid Prophylaxis in Adult Cardiac Surgery: A Dose-Response Meta-Analysis". <i>Circulation</i> , 2009, 120, e163.	1.6	2
302	CRT-D Therapy in Patients with Decompensated NYHA Class-Four CHF. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-4.	0.5	2
303	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. <i>BMJ Open</i> , 2014, 4, e005379-e005379.	0.8	2
304	Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. <i>Patient Related Outcome Measures</i> , 2016, 7, 13.	0.7	2
305	External validation of the multivariable "In-hospital Mortality for Pulmonary embolism using Claims Data" prediction rule in the Premier Hospital Database. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw046.	1.8	2
306	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. <i>International Journal of Clinical Practice</i> , 2017, 71, e12915.	0.8	2

#	ARTICLE	IF	CITATIONS
307	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. <i>Clinical Therapeutics</i> , 2017, 39, 1426-1436.e2.	1.1	2
308	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 37.	0.8	2
309	Credentials of Professionals Performing Echocardiography. <i>Journal of Diagnostic Medical Sonography</i> , 2017, 33, 91-99.	0.1	2
310	Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey. <i>Clinical Therapeutics</i> , 2020, 42, 1077-1086.	1.1	2
311	Cost-Effectiveness Analysis of Combination Statin/Ezetimibe Therapy for the Treatment of Elevated Low-Density Lipoprotein Cholesterol. <i>Hospital Pharmacy</i> , 2005, 40, 687-692.	0.4	1
312	Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know?. <i>Europace</i> , 2015, 17, 1316.2-1317.	0.7	1
313	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. <i>International Journal of Cardiology</i> , 2016, 222, 846-849.	0.8	1
314	Outcomes related to variation in hospital pulmonary embolus observation stay utilization. <i>Hospital Practice (1995)</i> , 2016, 44, 133-137.	0.5	1
315	Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2018, 34, 275-284.	0.9	1
316	P4813 Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure. <i>European Heart Journal</i> , 2018, 39, .	1.0	1
317	P4778 Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease. <i>European Heart Journal</i> , 2019, 40, .	1.0	1
318	Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation. <i>Journal of the National Medical Association</i> , 2020, 112, 395-401.	0.6	1
319	Welcome to the cardiovascular outcomes trials issue. <i>Future Cardiology</i> , 2021, 17, 399-402.	0.5	1
320	Appraising Evidence. , 2016, , 115-135.		1
321	Incomplete endothelialization of Watchman™ Device: Predictors and Implications from Two Cases. <i>Journal of Atrial Fibrillation</i> , 2019, 11, 2144.	0.5	1
322	Intravenous Corticosteroid Use Is Associated With Reduced Early Recurrence of Atrial Fibrillation Immediately Following Radiofrequency Catheter Ablation. <i>Journal of Atrial Fibrillation</i> , 2011, 4, 349.	0.5	1
323	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. <i>Journal of Health Economics and Outcomes Research</i> , 2019, 6, 160-173.	0.6	1
324	Patient Characteristics and Temporal Changes in Anticoagulation Treatment Patterns in Patients Diagnosed with Cancer-Associated Thrombosis: An Oscar-US Analysis. <i>Blood</i> , 2021, 138, 2132-2132.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Can a multidisciplinary initiative to increase adverse drug reaction reporting work?. Connecticut Medicine, 2004, 68, 281-4.	0.2	1
326	Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. Connecticut Medicine, 2005, 69, 19-22.	0.2	1
327	A comparison of different protease inhibitors on coronary heart disease risk. Connecticut Medicine, 2007, 71, 15-7.	0.2	1
328	The role of soluble fiber in the management of patients with hypercholesterolemia: a review of the literature. Connecticut Medicine, 2008, 72, 465-8.	0.2	1
329	Status epilepticus: a review of current pharmacologic treatments. Connecticut Medicine, 2009, 73, 525-8.	0.2	1
330	Benefit of echinacea for the prevention and treatment of the common cold? " Author's reply. Lancet Infectious Diseases, The, 2008, 8, 347-348.	4.6	0
331	Impact of amiodarone on the ability of anterior fat pad retention to prevent postcoronary arterial bypass grafting atrial fibrillation incidence: a substudy of the AFIST III (Atrial Fibrillation Suppression) Tj ETQq1 1 0.784314 rgBT /Over	0.7	0
332	Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes"Reply. JAMA - Journal of the American Medical Association, 2010, 304, 405.	3.8	0
333	Intent to Update Systematic Reviews. Journal of Investigative Medicine, 2011, 59, 811-815.	0.7	0
334	A Comparison of the Prognostic Accuracy of Three Clinical Prediction Rules for Post-Pulmonary Embolism In-Hospital Mortality. Chest, 2015, 148, 1009A.	0.4	0
335	Prescribers'™ behavior following below- versus above-range international normalized ratio values in warfarin-treated deep vein thrombosis patients. Current Medical Research and Opinion, 2016, 32, 1213-1215.	0.9	0
336	Health-care Cost Comparison of Rivaroxaban and Warfarin Use for VTE. Chest, 2016, 150, 1158A.	0.4	0
337	CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge. Current Medical Research and Opinion, 2018, 34, 1967-1974.	0.9	0
338	Can apixaban prevent venous thromboembolism better than rivaroxaban?. Lancet Haematology,the, 2019, 6, e179.	2.2	0
339	Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. Current Medical Research and Opinion, 2021, , 1-8.	0.9	0
340	Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism. Blood, 2014, 124, 4832-4832.	0.6	0
341	Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database. Blood, 2015, 126, 747-747.	0.6	0
342	Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?. Blood, 2015, 126, 2058-2058.	0.6	0

#	ARTICLE	IF	CITATIONS
343	External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer. <i>Blood</i> , 2016, 128, 4730-4730.	0.6	0
344	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. <i>Blood</i> , 2016, 128, 533-533.	0.6	0
345	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. <i>Blood</i> , 2016, 128, 2337-2337.	0.6	0
346	Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis. <i>Blood</i> , 2019, 134, 3673-3673.	0.6	0
347	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , 2020, 04, e344-e350.	0.7	0
348	Thromboembolism, Bleeding, and Vascular Death Among Older and Younger Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin. <i>Blood</i> , 2021, 138, 3234-3234.	0.6	0
349	A medication assistance program to increase access to health-care. <i>Connecticut Medicine</i> , 2001, 65, 711-3.	0.2	0
350	Budesonide: its role in Crohn's disease therapy. <i>Connecticut Medicine</i> , 2002, 66, 523-6.	0.2	0
351	Impact of Hispanic ethnicity on the likelihood of developing postoperative atrial fibrillation. <i>Connecticut Medicine</i> , 2006, 70, 77-9.	0.2	0
352	The impact of biologic agents to treat plaque psoriasis. <i>Connecticut Medicine</i> , 2009, 73, 79-83.	0.2	0